CD274 and ovarian carcinoma: Furthermore, Lei Z et al. found that the combination of anti-PD-L1 Atezolizumab and anti-vascular endothelial growth factor Bevacizumab prevented cisplatin-resistant ovarian cancer progression by suppressing STAT3-induced epithelial-mesenchymal transition [38].